Free Trial
→ Silicon Valley Gold Rush (From Stansberry Research) (Ad)
NASDAQ:PRFX

PainReform 5/15/2023 Earnings Report

PainReform logo
$2.29 -0.07 (-2.97%)
Closing price 04:00 PM Eastern
Extended Trading
$2.30 +0.00 (+0.22%)
As of 07:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Earnings HistoryForecast

PainReform EPS Results

Actual EPS
-$8.80
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

PainReform Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PainReform Announcement Details

Quarter
Date
5/15/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

PainReform's next earnings date is estimated for Wednesday, May 21, 2025, based on past reporting schedules.

Conference Call Resources

PainReform Earnings Headlines

PainReform Regains Nasdaq Compliance as of April 16, 2025
April 17, 2025 | tipranks.com
PainReform announces expansion into SEM sector
April 10, 2025 | markets.businessinsider.com
The Man I Turn to In Times Like This
A storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when publisher Brett Aitken turns to Whitney Tilson—a man CNBC once dubbed “The Prophet.” Tilson just released a new prediction that runs counter to what mainstream finance is telling you.
May 5, 2025 | Stansberry Research (Ad)
PainReform Shareholders Approve Key Proposals at April Meeting
April 10, 2025 | tipranks.com
PainReform Expands into Home Energy Management Sector, Leveraging DeepSolar’s AI-Driven Platform to Address the Growing Solar Optimization Market
April 10, 2025 | finance.yahoo.com
PainReform Expands into Home Energy Management Sector, Leveraging DeepSolar's AI-Driven Platform to Address the Growing Solar Optimization Market
April 10, 2025 | globenewswire.com
See More PainReform Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PainReform? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PainReform and other key companies, straight to your email.

About PainReform

PainReform (NASDAQ:PRFX), a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

View PainReform Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles